Madrigal Pharmaceuticals

#2486

Rank

$6.64B

Marketcap

United States

Country

Leadership team

Dr. Paul A. Friedman M.D. (Chairman & CEO)

Dr. Rebecca A. Taub M.D. (Founder, Chief Medical Officer, Pres of R&D and Director)

Mr. Alex G. Howarth (Sr. VP & CFO)

Products/ Services

Biotechnology, Medical Device, Pharmaceutical

Number of Employees

50 - 100

Headquarters

Washington, Pennsylvania, United States

Established

2011

Company Registration

SEC CIK number: 0001157601

Traded as

MDGL

URL

https://www.madrigalpharma.com

Overview

Location

Recognition and Award

References

Summary

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

History

Madrigal Pharmaceuticals was founded in 1992, and since then the company has been developing drug candidates that target metabolic and cardiovascular diseases, as well as other conditions. The company has developed a pipeline of potential treatments for its targeted conditions consisting of small molecules, monoclonal antibodies, and other biologics.

Mission

Madrigal Pharmaceuticals is committed to discovering, developing, and commercializing innovative and safe therapeutics to improve the lives of people living with metabolic and cardiovascular diseases.

Vision

Madrigal Pharmaceuticals is advancing our mission to develop safe and effective therapeutics by creating transformative treatments that will meaningfully improve patients' lives and reduce the burden of disease.

Key Team

Mr. Brian J. Lynch J.D. (Sr. VP & Gen. Counsel)

Mr. Remy Sukhija (Sr. VP & Chief Commercial Officer)

Dr. Kianoush Motesharei Ph.d. (Sr. VP of Bus. & Corp. Devel.)

Mr. Thomas W. Hare (Sr. VP of Clinical Management)

Mr. Edward Chiang (Sr. VP of Clinical & Technical Operations)

Dr. Robert E. Waltermire Ph.D. (Chief Pharmaceutical Devel. Officer)

Dr. Stephen Dodge M.B.A., Pharm.D. (Sr. VP of Global Medical Affairs)

Recognition and Awards

Madrigal Pharmaceuticals has been recognized for its efforts to advance treatments for metabolic and cardiovascular diseases. The company has received numerous industry awards, including the Prix Galien USA Award for Best Biotechnology Product for MGL-3196.